We found that AURKA inhibition as a single agent in a mouse xenograft model of RCC had a modest effect on reducing tumor burden when tumors were already palpable, but was competent in preventing tumors from taking when treated at an earlier time point. This evidence concerns the gene AURKA and renal cell carcinoma.